Raises FY26 adjusted operating profit view to down 4%-12% from down 5%-13%. The company said, ” The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Morning News Wrap-Up, 5/6/26: Today’s Biggest Stock Market Stories!
- These Are the Stocks Reporting Earnings Today – May 6, 2026
- Novo Nordisk Earnings: NVO Stock Rises as Wegovy Sales Drive Massive Q1 Beat
- Novo Nordisk Q1 2026 Boosted by 340B Reversal as Wegovy Pill Delivers Record U.S. Launch
- Novo Nordisk Completes Key CagriSema Obesity Study, Raising the Stakes in the Weight-Loss Drug Race